SCHEMBL5105437

SCHEMBL5105437

O=C(O)c1n[nH]cc1NC(=O)[C@@H]1CCCO1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 4/20 0.51
KDM4E B2RXH2 3/20 0.51
TSHR P16473 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
POLB P06746 3/20 0.48
HTT P42858 2/20 0.48
ADORA3 P0DMS8 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
KMT2A Q03164 1/20 0.48
HPGD P15428 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8272416 1.00 MAPK1 (0.53) MAPK1HSD17B10KDM4ETSHRSMN1; SMN2
SCHEMBL14289389 0.87 SMN1; SMN2 (0.59) MAPK1HSD17B10KDM4ESMN1; SMN2NPC1
SCHEMBL5111539 0.87 SMN1; SMN2 (0.59) MAPK1HSD17B10KDM4ESMN1; SMN2NPC1
SCHEMBL8262998 0.86 SMN1; SMN2 (0.49) MAPK1HSD17B10KDM4ESMN1; SMN2NPC1
SCHEMBL2799869 0.78 HPGD (0.46) HSD17B10KDM4ETSHRSMN1; SMN2NPC1
SCHEMBL2678509 0.75 HSD17B10 (0.56) MAPK1HSD17B10KDM4ETSHRSMN1; SMN2
SCHEMBL2678505 0.75 HSD17B10 (0.56) MAPK1HSD17B10KDM4ETSHRSMN1; SMN2
SCHEMBL2678590 0.75 HSD17B10 (0.56) MAPK1HSD17B10KDM4ETSHRSMN1; SMN2
SCHEMBL13314749 0.74 SMN1; SMN2 (0.50) MAPK1HSD17B10KDM4ETSHRSMN1; SMN2
SCHEMBL22258776 0.72 ALDH1A1 (0.40) MAPK1HSD17B10KDM4ESMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
EP-1781653-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors CDK3, CDK1, GSK3B MAPK1 608/4885HSD17B10 1196/4885KDM4E 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.